Yahoo Finance RxSight Inc (RXST) Surpasses Analyst Revenue Forecasts in Q1 2024
Revenue: Reported $29.5 million, up 69% year-over-year, surpassing estimates of $27.56 million.
Net Loss: Recorded at $(9.1) million, an improvement from $(13.2) million year-over-year, and better than estimates of $(10.73) million.
Earnings Per Share (EPS): Reported $(0.25), an improvement from $(0.42) year-over-year, better than the estimated $(0.27).
Gross Margin: Reached 70%, up from 59% in the same quarter last year, indicating significant operational efficiency improvements.
Operating Expenses: Increased to $31.4 million, up 34% year-over-year, reflecting ongoing investments in expanding the installed base and sales volume of Light Adjustable Lenses.
2024 Full-Year Guidance: Revenue forecast raised to $132.0 million to $137.0 million, indicating expected growth of 48% to 54% over the previous year.
Cash Position: Ended the quarter with $125.4 million in cash, cash equivalents, and short-term investments, providing a solid financial foundation for continued growth.
RxSight Inc (NASDAQ:RXST) released its 8-K filing on May 6, 2024, detailing its financial results for the first quarter ended March 31, 2024. The company, known for its innovative Light Adjustable Lens technology for post-cataract surgery care, reported a robust increase in revenue and significant improvements in gross margin, surpassing analyst expectations for the quarter.
RxSight Inc, a leader in the ophthalmic medical device sector, focuses on enhancing vision quality for patients post-cataract surgery through its adjustable intraocular lens technology. This technology allows for post-operative adjustments to optimize patient vision, setting a new standard in the field.
Financial Performance Highlights
For Q1 2024, RxSight reported revenues of $29.5 million, a substantial 69% increase from $17.5 million in the same quarter the previous year. This growth was primarily driven by a 92% increase in sales of Light Adjustable Lenses and a 35% increase in Light Delivery Devices revenue. The company's gross profit saw an impressive rise to $20.7 million or 70% of revenue, up from $10.4 million or 59% of revenue in Q1 2023. The improved gross margin was attributed to a favorable shift in product mix and reduced production costs due to higher volumes and lower material costs.
Despite these gains, RxSight incurred a net loss of $9.1 million, or $0.25 per share, an improvement from a net loss of $13.2 million, or $0.42 per share, in the prior year's quarter. Adjusted for non-cash expenses like stock-based compensation, the adjusted net loss was $4.4 million, or $0.12 per share, better than the adjusted net loss of $9.9 million, or $0.31 per share, a year ago.
Operational and Strategic Developments
The company's operational expenses for the quarter totaled $31.4 million, reflecting a 34% increase from the previous year, due to strategic investments aimed at expanding the installed base of Light Delivery Devices and supporting increased sales volumes of Light Adjustable Lenses. The company ended the quarter with $125.4 million in cash, cash equivalents, and short-term investments.
RxSight's CEO, Ron Kurtz, commented on the results, stating, "We are pleased with a strong start to the year, fueled by the continued adoption of our Light Adjustable Lens technology." He emphasized the increasing interest from doctors and patients and expressed confidence in setting a new standard for premium intraocular lens offerings in the U.S.
Updated Financial Guidance for 2024
RxSight has raised its full-year 2024 revenue forecast to between $132.0 million and $137.0 million, indicating expected growth of 48% to 54% year-over-year. The company also anticipates gross margins to improve to between 68% and 70%, and projects operating expenses to be between $126.0 million and $130.0 million.
The company's strong performance in Q1, combined with its optimistic outlook for the rest of the year, reflects its effective strategy and operational execution. RxSight's advancements in medical device technology not only enhance patient outcomes but also position the company as a significant player in the ophthalmic sector.
Conclusion
RxSight Inc's Q1 2024 results demonstrate a promising start to the year, with revenue and margin improvements that highlight the company's potential for sustained growth. As RxSight continues to expand its market presence and enhance its technological offerings, it remains a noteworthy company for investors and industry stakeholders interested in medical device innovations.
Explore the complete 8-K earnings release (here) from RxSight Inc for further details.
This article first appeared on GuruFocus.
